No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the testicular cancer intergroup study

Craig R. Nichols, Bruce J. Roth, Stephen D. Williams, Indrani Gill, Franco M. Muggia, Donald M. Stablein, Raymond B. Weiss, Lawrence Einhorn

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Purpose; The purpose of this study is to evaluate the risk of acute vascular events in patients receiving cisplatin-based chemotherapy for testicular cancer. Patients and Methods: A questionnaire assessing cardiovascular toxicity was distributed to all participants in the Testicular Cancer Intergroup study and details of toxicity from the chemotherapy flow sheets were reviewed. Patients with pathologic stage I testicular cancer were registered on to the study and observed after retroperitoneal lymphadenectomy. Patients with pathologic stage II disease were randomized to receive two postoperative courses of adjuvant cisplatin-based chemotherapy or observation. Any patient who had disease recurrence after observation or adjuvant therapy was given four cycles of cisplatin-based chemotherapy. Results: Review treatment-related toxicity for those patients receiving adjuvant chemotherapy (n = 97) or chemotherapy for recurrent disease (n = 83) showed no cases of acute cardiovascular toxicity. The median follow-low-up period after study enrollment was 5.1 years; 459 questionnaires were mailed and 270 were returned. The percent return was equal among the observed adjuvant and recurrent groups (59%, 54%, and 64%). There was a significant increase in the incidence of extremity paresthesias in the two groups receiving chemotherapy. Fatal myocardial infarction was reported in two patients in the observation group and one nonfatal infarction was reported in the adjuvant treatment group. No patient in any group reported an incidence of stroke. Three patients in the observation group and one patient in the recurrent group experienced a thromboembolic event. Conclusion: Despite sporadic case reports suggesting a causal association between chemotherapy for testicular cancer and acute vascular events, this retrospective analysis provides no evidence of an increased risk for subsequent cardiovascular disease in this patient population.

Original languageEnglish (US)
Pages (from-to)760-765
Number of pages6
JournalJournal of Clinical Oncology
Volume10
Issue number5
StatePublished - 1992

Fingerprint

Testicular Neoplasms
Drug Therapy
Observation
Cisplatin
Blood Vessels
Paresthesia
Incidence
Adjuvant Chemotherapy
Lymph Node Excision
Infarction
Cardiovascular Diseases
Therapeutics
Extremities
Stroke
Myocardial Infarction
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

No evidence of acute cardiovascular complications of chemotherapy for testicular cancer : An analysis of the testicular cancer intergroup study. / Nichols, Craig R.; Roth, Bruce J.; Williams, Stephen D.; Gill, Indrani; Muggia, Franco M.; Stablein, Donald M.; Weiss, Raymond B.; Einhorn, Lawrence.

In: Journal of Clinical Oncology, Vol. 10, No. 5, 1992, p. 760-765.

Research output: Contribution to journalArticle

Nichols, CR, Roth, BJ, Williams, SD, Gill, I, Muggia, FM, Stablein, DM, Weiss, RB & Einhorn, L 1992, 'No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the testicular cancer intergroup study', Journal of Clinical Oncology, vol. 10, no. 5, pp. 760-765.
Nichols, Craig R. ; Roth, Bruce J. ; Williams, Stephen D. ; Gill, Indrani ; Muggia, Franco M. ; Stablein, Donald M. ; Weiss, Raymond B. ; Einhorn, Lawrence. / No evidence of acute cardiovascular complications of chemotherapy for testicular cancer : An analysis of the testicular cancer intergroup study. In: Journal of Clinical Oncology. 1992 ; Vol. 10, No. 5. pp. 760-765.
@article{7b15c8ff16d647d19224c8e3996fa3d7,
title = "No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the testicular cancer intergroup study",
abstract = "Purpose; The purpose of this study is to evaluate the risk of acute vascular events in patients receiving cisplatin-based chemotherapy for testicular cancer. Patients and Methods: A questionnaire assessing cardiovascular toxicity was distributed to all participants in the Testicular Cancer Intergroup study and details of toxicity from the chemotherapy flow sheets were reviewed. Patients with pathologic stage I testicular cancer were registered on to the study and observed after retroperitoneal lymphadenectomy. Patients with pathologic stage II disease were randomized to receive two postoperative courses of adjuvant cisplatin-based chemotherapy or observation. Any patient who had disease recurrence after observation or adjuvant therapy was given four cycles of cisplatin-based chemotherapy. Results: Review treatment-related toxicity for those patients receiving adjuvant chemotherapy (n = 97) or chemotherapy for recurrent disease (n = 83) showed no cases of acute cardiovascular toxicity. The median follow-low-up period after study enrollment was 5.1 years; 459 questionnaires were mailed and 270 were returned. The percent return was equal among the observed adjuvant and recurrent groups (59{\%}, 54{\%}, and 64{\%}). There was a significant increase in the incidence of extremity paresthesias in the two groups receiving chemotherapy. Fatal myocardial infarction was reported in two patients in the observation group and one nonfatal infarction was reported in the adjuvant treatment group. No patient in any group reported an incidence of stroke. Three patients in the observation group and one patient in the recurrent group experienced a thromboembolic event. Conclusion: Despite sporadic case reports suggesting a causal association between chemotherapy for testicular cancer and acute vascular events, this retrospective analysis provides no evidence of an increased risk for subsequent cardiovascular disease in this patient population.",
author = "Nichols, {Craig R.} and Roth, {Bruce J.} and Williams, {Stephen D.} and Indrani Gill and Muggia, {Franco M.} and Stablein, {Donald M.} and Weiss, {Raymond B.} and Lawrence Einhorn",
year = "1992",
language = "English (US)",
volume = "10",
pages = "760--765",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - No evidence of acute cardiovascular complications of chemotherapy for testicular cancer

T2 - An analysis of the testicular cancer intergroup study

AU - Nichols, Craig R.

AU - Roth, Bruce J.

AU - Williams, Stephen D.

AU - Gill, Indrani

AU - Muggia, Franco M.

AU - Stablein, Donald M.

AU - Weiss, Raymond B.

AU - Einhorn, Lawrence

PY - 1992

Y1 - 1992

N2 - Purpose; The purpose of this study is to evaluate the risk of acute vascular events in patients receiving cisplatin-based chemotherapy for testicular cancer. Patients and Methods: A questionnaire assessing cardiovascular toxicity was distributed to all participants in the Testicular Cancer Intergroup study and details of toxicity from the chemotherapy flow sheets were reviewed. Patients with pathologic stage I testicular cancer were registered on to the study and observed after retroperitoneal lymphadenectomy. Patients with pathologic stage II disease were randomized to receive two postoperative courses of adjuvant cisplatin-based chemotherapy or observation. Any patient who had disease recurrence after observation or adjuvant therapy was given four cycles of cisplatin-based chemotherapy. Results: Review treatment-related toxicity for those patients receiving adjuvant chemotherapy (n = 97) or chemotherapy for recurrent disease (n = 83) showed no cases of acute cardiovascular toxicity. The median follow-low-up period after study enrollment was 5.1 years; 459 questionnaires were mailed and 270 were returned. The percent return was equal among the observed adjuvant and recurrent groups (59%, 54%, and 64%). There was a significant increase in the incidence of extremity paresthesias in the two groups receiving chemotherapy. Fatal myocardial infarction was reported in two patients in the observation group and one nonfatal infarction was reported in the adjuvant treatment group. No patient in any group reported an incidence of stroke. Three patients in the observation group and one patient in the recurrent group experienced a thromboembolic event. Conclusion: Despite sporadic case reports suggesting a causal association between chemotherapy for testicular cancer and acute vascular events, this retrospective analysis provides no evidence of an increased risk for subsequent cardiovascular disease in this patient population.

AB - Purpose; The purpose of this study is to evaluate the risk of acute vascular events in patients receiving cisplatin-based chemotherapy for testicular cancer. Patients and Methods: A questionnaire assessing cardiovascular toxicity was distributed to all participants in the Testicular Cancer Intergroup study and details of toxicity from the chemotherapy flow sheets were reviewed. Patients with pathologic stage I testicular cancer were registered on to the study and observed after retroperitoneal lymphadenectomy. Patients with pathologic stage II disease were randomized to receive two postoperative courses of adjuvant cisplatin-based chemotherapy or observation. Any patient who had disease recurrence after observation or adjuvant therapy was given four cycles of cisplatin-based chemotherapy. Results: Review treatment-related toxicity for those patients receiving adjuvant chemotherapy (n = 97) or chemotherapy for recurrent disease (n = 83) showed no cases of acute cardiovascular toxicity. The median follow-low-up period after study enrollment was 5.1 years; 459 questionnaires were mailed and 270 were returned. The percent return was equal among the observed adjuvant and recurrent groups (59%, 54%, and 64%). There was a significant increase in the incidence of extremity paresthesias in the two groups receiving chemotherapy. Fatal myocardial infarction was reported in two patients in the observation group and one nonfatal infarction was reported in the adjuvant treatment group. No patient in any group reported an incidence of stroke. Three patients in the observation group and one patient in the recurrent group experienced a thromboembolic event. Conclusion: Despite sporadic case reports suggesting a causal association between chemotherapy for testicular cancer and acute vascular events, this retrospective analysis provides no evidence of an increased risk for subsequent cardiovascular disease in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=0026637387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026637387&partnerID=8YFLogxK

M3 - Article

C2 - 1285740

AN - SCOPUS:0026637387

VL - 10

SP - 760

EP - 765

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -